<DOC>
	<DOC>NCT01032304</DOC>
	<brief_summary>The aim of the study is to evaluate the effect of erdosteine, compared to placebo, on exacerbation rate over a 12-month treatment period in patients with moderate-to-severe COPD. Moreover, the effects of erdosteine on pulmonary function parameters, clinical symptoms and quality of life, and the long-term safety of the drug will be assessed.</brief_summary>
	<brief_title>The Efficacy and Safety of Erdosteine in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Erdosteine</mesh_term>
	<criteria>COPD stage IIIII GOLD At least 2 exacerbations in the previous 212 months Acute exacerbations in the 2 months prior to enrolment Diagnosis of asthma and/or other relevant lung diseases COPD stage IV Unstable concurrent diseases</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>